Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | PPM1B | O75688 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15440736 | 0.90 | CYP1A2 (0.34) | CYP1A2CYP2C9TSHRCYP2C19ATM | |
| SCHEMBL3679801 | 0.79 | L3MBTL1 (0.34) | CYP1A2CYP2C9TSHRCYP2C19ATM | |
| SCHEMBL11301100 | 0.79 | L3MBTL1 (0.34) | CYP1A2CYP2C9TSHRCYP2C19ATM | |
| SCHEMBL4280912 | 0.79 | GRM4 (0.35) | CYP1A2CYP2C9TSHRCYP2C19LMNA | |
| SCHEMBL2761507 | 0.78 | POLB (0.33) | CYP1A2CYP2C9TSHRCYP2C19ATM | |
| SCHEMBL2162059 | 0.76 | ATM (0.35) | CYP1A2CYP2C9TSHRCYP2C19ATM | |
| SCHEMBL30369948 | 0.76 | ATM (0.35) | CYP1A2CYP2C9TSHRCYP2C19ATM | |
| SCHEMBL30950334 | 0.75 | ALDH1A1 (0.33) | L3MBTL1 | |
| SCHEMBL3953559 | 0.75 | ATM (0.34) | CYP1A2CYP2C9TSHRCYP2C19ATM | |
| SCHEMBL11063629 | 0.71 | ATM (0.37) | CYP1A2CYP2C9TSHRCYP2C19ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617788-B2 | Bridged bicyclic compounds as BTK inhibitors | Beijing Innocare Pharma Tech. Co. Ltd. (CN) | 2026-05-05 | — | — | US | disclosed |
| CN-119173512-A | Small molecule inhibitors of ubiquitin-specific protease 1 (USP 1) and uses thereof | 英矽智能科技知识产权有限公司 | 2024-12-20 | — | — | CN | disclosed |
| CN-116670119-A | Bridged bicyclic compounds as BTK inhibitors | 北京诺诚健华医药科技有限公司 | 2023-08-29 | — | — | CN | disclosed |
| US-20230212175-A1 | BRIDGED BICYCLIC COMPOUNDS AS BTK INHIBITORS | BEIJING INNOCARE PHARMA TECH. CO., LTD. (CN) | 2023-07-06 | — | — | US | disclosed |
| EP-4200283-A1 | BRIDGED BICYCLIC COMPOUNDS AS BTK INHIBITORS | Beijing InnoCare Pharma Tech Co., Ltd. (CN) | 2023-06-28 | — | — | EP | disclosed |
| US-20220081430-A1 | SUBSTITUTED AMIDE COMPOUNDS USEFUL AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-03-17 | — | — | US | disclosed |
| EP-3924337-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | Bristol-Myers Squibb Company (US) | 2021-12-22 | — | — | EP | disclosed |
| EP-3924336-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | Bristol-Myers Squibb Company (US) | 2021-12-22 | — | — | EP | disclosed |
| EP-3890750-A1 | CARBORANE COMPOUNDS, CARBORANE ANALOGS, AND METHODS OF USE THEREOF | Ohio State Innovation Foundation (US) | 2021-10-13 | — | — | EP | disclosed |
| EP-3727386-A1 | INHIBITORS OF PROTEASE ACTIVATED RECEPTOR-2 | Takeda Pharmaceutical Company Limited (JP) | 2020-10-28 | — | — | EP | disclosed |
| WO-2020117799-A1 | CARBORANE COMPOUNDS, CARBORANE ANALOGS, AND METHODS OF USE THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2020-06-11 | — | — | WO | disclosed |
| EP-3240546-A1 | TERTIARY ALCOHOL IMIDAZOPYRAZINE BTK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-11-08 | — | — | EP | disclosed |
| EP-3226689-A1 | NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | Merck Sharp & Dohme Corp. (US) | 2017-10-11 | — | — | EP | disclosed |
| EP-3226690-A1 | NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | Merck Sharp & Dohme Corp. (US) | 2017-10-11 | — | — | EP | disclosed |
| EP-3055302-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2016-08-17 | — | — | EP | disclosed |
| WO-2016109222-A1 | TERTIARY ALCOHOL IMIDAZOPYRAZINE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-07-07 | — | — | WO | disclosed |
| WO-2016089830-A1 | NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | MERCK SHARP & DOHME CORP. (US) | 2016-06-09 | — | — | WO | disclosed |
| WO-2016089833-A1 | NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | MERCK SHARP & DOHME CORP. (US) | 2016-06-09 | — | — | WO | disclosed |
| WO-2015052264-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-04-16 | — | — | WO | disclosed |
| EP-2414352-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2012-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12617788-B2 | Bridged bicyclic compounds as BTK inhibitors | BTK, LCK, TEC | CYP1A2 3440/4885CYP2C9 1514/4885TSHR 534/4885 |
| US-20230212175-A1 | BRIDGED BICYCLIC COMPOUNDS AS BTK INHIBITORS | BTK, LCK, LYN | CYP1A2 3532/4885CYP2C9 1120/4885TSHR 3094/4885 |
| US-20220081430-A1 | SUBSTITUTED AMIDE COMPOUNDS USEFUL AS FARNESOID X RECEPTOR MODULATORS | NR1H4, NR1H3, NR1H2 | CYP1A2 719/4885CYP2C9 965/4885TSHR 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.